NYSE
1.11USD
+0.03 (+2.78%)
We have scored 4 news catalysts on Annovis Bio, Inc. (ANVS) over the past 12 months. The biggest single-day move next to one of them came Sep 3, 2026, when ANVS closed −18.8%: “Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA”. Coverage across the window leans positive (average ticker sentiment +0.25). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
47.4M
P/E
—
EPS
—
Beta
1.23
52W range
0.9295-5.5
Day range
1.07–1.14
Open
1.07
Prev close
1.08
Volume
590.4K
Avg volume
881.8K
Dividend
0.00
IPO
2020-01-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Annovis Bio, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ANVS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
